AMGEN INC — Director's Dealing 2023

May 10, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2023-05-05

Reporting Person: Graham Jonathan P (EVP, Gen. Counsel & Secy.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-05	Common Stock	F	592	$231.89	Disposed	39573	Direct

Footnotes

F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,120 RSUs which will vest on 11/1/2023; 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 734 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.